Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 5
Submit an article Journal homepage
1,033
Views
89
CrossRef citations to date
0
Altmetric
Original Articles: Research

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Hyun-Gyung GohMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Min LinFluidigm Corporation, South San Francisco, CA, USA
,
Takashi FukushimaFluidigm KK, Tokyo, Japan
,
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy
,
Dongho KimMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Soo-Young ChoiMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Soo-Hyun KimMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Jeong LeeMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Young-Seok LeeMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
,
Sang-Mi OhMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, Korea
&
Dong-Wook KimMolecular Genetics Research Institute, The Catholic University of Korea, Seoul, KoreaCorrespondence[email protected]
 show all
Pages 896-904 | Received 12 Oct 2010, Accepted 12 Jan 2011, Published online: 21 Feb 2011

References

  • Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375–2384.
  • Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:130–134.
  • Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic myeloid leukemia with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080–7085.
  • Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008;112:837–845.
  • Ross DM, Hughes T. How complete is ‘complete’ molecular response in imatinib-treated chronic myeloid leukemia? Leuk Lymphoma 2008;49:1230–1231.
  • Bruemmendorf TH, Cervanantes F, Kim DW, et al. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 2008;26(15 Suppl.): Abstract 7001.
  • O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112(Suppl. 1): Abstract 186.
  • Gianantonio R, Francesca P, Fausto C, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933–4938.
  • Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009;23:1628–1633.
  • Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392–397.
  • Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398–404.
  • Branford S, Seymour JF, Grigg A, Arthur C, Lynch K, Hughes TP. Increasing frequency and marked stability of complete molecular responses is observed in imatinib-treated CML patients with long-term follow up. Blood 2006;108(Suppl. 1): Abstract 430.
  • Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28(Suppl. 1): S71–S73.
  • Hromadnikova I, Houbova B, Hridelova D, et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Prenatal Diagn 2003;23:235–238.
  • Oehler VG, Qin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2009;23:396–399.
  • Bhat S, Herrmann J, Armishaw P, Corbisier P, Emslie KR. Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number. Anal Bioanal Chem 2009;394:457–467.
  • Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009;50:944–951.
  • Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
  • Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118–3122.
  • Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362–3367.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.